Transdiagnostic Group Therapy (GBAT) for Autistic Adults With Personalized Therapeutics

Last updated: October 28, 2024
Sponsor: Rutgers, The State University of New Jersey
Overall Status: Completed

Phase

N/A

Condition

Autism

Autism Spectrum Disorder (Asd)

Treatment

Watchful Waiting and Groups - Phase 2

GBAT+IE

GBAT+I, GBAT+E - Phase I

Clinical Study ID

NCT05512221
Pro2022001343
  • Ages 18-40
  • All Genders

Study Summary

The purpose of this study is to build upon an earlier study that evaluated the use of a 10-week transdiagnostic Group Behavioral Activation Therapy (GBAT), a telehealth delivered intervention, as a cost effective and accessible way to treat symptoms of anxiety and depression in autistic adults. The current study will pilot and compare relative feasibility, acceptability, and preliminary efficacy of three adapted GBAT groups and a Watchful Waiting (WW) group. The three groups include GBAT+Individual (GBAT+I; individual sessions to supplement the 10 group sessions), GBAT+Engagement Booster (GBAT+E; supplemental materials), and GBAT+Both (GBAT+IE individual sessions and supplemental materials).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Live in New Jersey or New York

  • Be 18-40 years old

  • Have a confirmed diagnosis of Autism Spectrum Disorders (ASD).

  • Have access to a device (e.g., computer with a webcam or smartphone) in order tocomplete online surveys and participate in videoconference sessions

  • WRAT Reading Comprehension grade equivalent 6th grade or higher

  • Receive a best-estimate diagnosis of an anxiety or mood disorder (GeneralizedAnxiety Disorder, Social Anxiety Disorder, Specific Phobia, Panic Disorder,Agoraphobia, Major Depressive Disorder, Unspecified Depression, PersistentDepressive Disorder).

  • Be interested in participating in an online telehealth treatment group to addresstheir difficulties in the aforementioned areas

  • Approximately 60% of our sample will be White, Non-Hispanic; approximately 40% ofour sample will be female-identifying and 40% will be male-identifying

Exclusion

Exclusion Criteria:

  • Are younger than 18 years old, or older than 40 years old

  • Do not have an ASD diagnosis

  • Have WRAT Reading Comprehension below 6th grade level

  • Are unable to understand English fluently

  • Have a principal DSM-5 disorder other than one of the above listed anxiety ordepression disorders, have received a diagnosis of Intellectual Disability,schizophrenia, or bipolar disorder or demonstrate suicidal ideation or intent severeenough to require current hospitalization, or who have attempted suicide in the past 3 months.

  • Are currently enrolled in another behavioral therapy or psychotherapy targetingdepression, anxiety or anger.

  • Are experiencing suicidal ideation that requires current hospitalization.

  • The PI's best clinical judgment that it would not be in the adult's best interest tobe enrolled (e.g., due to factors that may affect their engagement or comfort in thegroup).

Study Design

Total Participants: 33
Treatment Group(s): 3
Primary Treatment: Watchful Waiting and Groups - Phase 2
Phase:
Study Start date:
September 23, 2022
Estimated Completion Date:
July 01, 2024

Connect with a study center

  • Rutgers University

    Piscataway, New Jersey 08854
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.